Gary J. G. Atkinson
Gründer bei Zylö Therapeutic, Inc.
Profil
Gary J.
G.
Atkinson founded Zylö Therapeutic, Inc. in 2017, where he is working as Director from 2017.
Mr. Atkinson also formerly worked at Ionis Pharmaceuticals, Inc., as Vice President-Finance from 1995 to 2000, Quorex Pharmaceuticals, Inc., as Chief Financial Officer & Senior Vice President from 2001 to 2005, and Lpath, Inc., as Chief Financial Officer, Secretary & VP from 2005 to 2012.
Mr. Atkinson received his undergraduate degree from Brigham Young University.
Aktive Positionen von Gary J. G. Atkinson
Unternehmen | Position | Beginn |
---|---|---|
Zylö Therapeutic, Inc.
Zylö Therapeutic, Inc. BiotechnologyHealth Technology Zylö Therapeutic, Inc. develops a drug-delivery system designed to deliver notoriously hard-to-deliver therapeutic agents. The frim offers patented platform technology that leverages hydrogel-derived nanoparticles to deliver in a sustained and controlled manner therapeutic agents through topical administration, enabling the healthcare industry to harness the therapeutic potential across a variety of applications. The company was founded by Scott R. Pancoast, Joel M. Friedman, Adam Friedman, Lance M. White and Gary J. G. Atkinsonin November 2017 in and is headquartered in Greenville, SC. | Gründer | 01.11.2017 |
Ehemalige bekannte Positionen von Gary J. G. Atkinson
Unternehmen | Position | Ende |
---|---|---|
Quorex Pharmaceuticals, Inc.
Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA. | Finanzdirektor/CFO | 01.01.2005 |
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2000 |
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Vorstandsvorsitzender | - |
Ausbildung von Gary J. G. Atkinson
Brigham Young University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Quorex Pharmaceuticals, Inc.
Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA. | Health Technology |
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | Health Technology |
Zylö Therapeutic, Inc.
Zylö Therapeutic, Inc. BiotechnologyHealth Technology Zylö Therapeutic, Inc. develops a drug-delivery system designed to deliver notoriously hard-to-deliver therapeutic agents. The frim offers patented platform technology that leverages hydrogel-derived nanoparticles to deliver in a sustained and controlled manner therapeutic agents through topical administration, enabling the healthcare industry to harness the therapeutic potential across a variety of applications. The company was founded by Scott R. Pancoast, Joel M. Friedman, Adam Friedman, Lance M. White and Gary J. G. Atkinsonin November 2017 in and is headquartered in Greenville, SC. | Health Technology |